Microfluidics, Nanotechnology and Disease Biomarkers for Personalized Medicine Applications


Muhammad J. A. Shiddiky (Editor)
UQ Postdoctoral Research Fellow, Centre for Biomarker Research and Development, Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, QLD, Australia

Eugene J. H. Wee (Editor)

Sakandar Rauf (Editor)

Matt Trau (Editor)

Series: New Developments in Medical Research
BISAC: MED106000

In recent years, thousands of cancer biomarkers have been discovered and described in scientific literature. The promise of personalized medicine, where diseases such as cancer are accurately diagnosed and treatments tailored specifically for individuals, is becoming a reality. Significant advances in biomarker-based research methodologies such as Next Generation Sequencing (NGS) are at the cusp of ushering in a new era of personal medicine. However, unlike the spectacular advances in research technologies for disease biomarker discovery, biomarker-based technologies that can effectively be used in the clinic (or point-of-care) to enable personalized medicine are still lacking.

In this book, we feature a selection of emerging technologies which are aimed at enabling clinical applications of personalised medicine. Each of the eight chapters is written by a leading group at the intersection of microfluidics, biology, and nanotechnology. For instance, to accelerate a major bottleneck in the development of clinically useful protein diagnostics, we discuss the application of yeast-derived single chain Fragment variable (scFv) antibody-like molecules as a potential low cost alternative to traditional antibody-based diagnostics. Circulating tumour cells (CTCs) are an emerging class of cancer biomarkers and a potential resource for understanding cancer progression; we explore various strategies combining microfluidics with nanotechnology for capturing CTCs.

The book includes an evaluation of some current and emerging technologies for detecting clinical DNA methylation, another potential cancer biomarker. As personalized medicine may involve tracking a patient’s response to treatment, the application of microfluidics to detect metabolites in biological fluids is also discussed. Finally, the ultimate goal of personalized medicine is targeted therapy. One promising approach is RNAi technology which uses short nucleotides to disrupt cancer pathways. In this book, nanoparticle approaches to deliver these short nucleotides are discussed. (Imprint: Nova Biomedical )



Table of Contents


Chapter 1. Bio-MEMS (Microfluidics) for CTC Detection in Cancer Patients
(Shailender Singh Kanwar, Meggie M.G. Grafton and Sunitha Nagrath, Department of Chemical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI, USA)

Chapter 2. Microfluidic Flow Fractionation for Isolation of Circulating Tumor Cells
(Kyung-A Hyun and Hyo-Il Jung, School of Mechanical Engineering, Yonsei University, Seoul, South Korea)

Chapter 3. Micro/Nanostructured Substrates for Cell Typing, Isolation, and Disease Diagnostics
(Mohammed A.I. Mahmood, Yuan Wan, and Samir M. Iqbal, University of Texas at Arlington, Arlington, TX, USA, and others)

Chapter 4. Microfluidic Devices for the Analysis of Drugs and Their Metabolites in Biological Fluids
(Aliaa I. Shallan, Rosanne M. Guijt and Michael C. Breadmore,
Australian Centre for Research on Separation Science, School of Chemistry, University of Tasmania, Tasmania, Australia)

Chapter 5. Advances in scFv Display Technologies for Biomarker Verification and Detection
(Sean A. Gray, Brian G. Oliver and Gerard A. Cangelosi, Seattle Biomedical Research Institute, Seattle, WA, USA, and others)

Chapter 6. Detecting DNA Methylation for Cancer Diagnostics and Prognostics
(Eugene J.H. Wee, Muhammad J.A. Shiddiky and Matt Trau, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia, Australia)

Chapter 7. Molecular Biomarkers for Cancer
(Pravin D. Potdar, Department of Molecular Medicine and Biology, Jaslok Hospital and Research Center, Maharashtra, India)

Chapter 8. Nanotechnology, Tumour Biomarker and RNA Interference for Personalized Medicine Applications
(Rafael B. Erlich, Phoebe Phillips, Maria Kavallaris and Joshua McCarroll, Tumour Biology and Targeting Program, Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, NSW, Australia, and others)


Additional information


, ,